Skip to Main Content

Paper Details

Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms.
Blood
57
2022
CH, CH mutations, CK1, HSPCs, Lenalidomide, TP53, TP53 mutations, TP53-mutated t-MNs, Trp53, Trp53-mutant, Trp53-mutant HSPCs, Trp53-mutant hematopoietic stem and progenitor cells, driver gene, lenalidomide, myeloid neoplasms, patients, pomalidomide, t, t-MN, t-MNs, thalidomide, therapy-related myeloid neoplasms
Author NameAffiliation
Rashmi Kanagal-ShamannaThe University of Texas MD Anderson Cancer Center
Jianhua ZhangThe University of Texas MD Anderson Cancer Center
Jianhua ZhangThe University of Texas MD Anderson Cancer Center
Curtis GumbsThe University of Texas MD Anderson Cancer Center
Courtney D DiNardoThe University of Texas MD Anderson Cancer Center
Farhad RavandiThe University of Texas MD Anderson Cancer Center
Hagop KantarjianThe University of Texas MD Anderson Cancer Center
Guillermo Garcia-ManeroThe University of Texas MD Anderson Cancer Center
Phillip A FutrealThe University of Texas MD Anderson Cancer Center
Benjamin L EbertDana-Farber Cancer Institute
Benjamin L EbertHoward Hughes Medical Institute, Dana-Farber Cancer Institute
  • 1 - 11

Datasets

Release 1.2